RECORD · 07 / SOURCES

The tesamorelin reference register

Every figure on this site traces to one of these sources — the pivotal trials, the FDA prescribing label, the LiverTox monograph, the pharmacokinetic and safety studies, and the 2026 meta-analysis.

How this register is used

Each numbered entry below corresponds to the inline [N] markers across the research, side-effects, vs-sermorelin, dosage, and FAQ pages. Where a finding states a number — a percentage, a dose, a half-life, a p-value — that number is carried back to one of these sources. Regulatory and safety framing draws on the FDA prescribing label [1] and the NIH LiverTox monograph [4]; the efficacy record rests on the pivotal and long-term HIV trials [5][6] and the 2026 meta-analysis [15]. The full reference list is the record's evidentiary spine — the field that makes every other field verifiable.

  1. Theratechnologies Inc. Tesamorelin for injection — Full Prescribing Information (FDA-approved labeling, NDA 022505). U.S. FDA Prescribing Information. 2025.
  2. Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538.
  3. Teng S, et al. Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2013;2:237-45.
  4. National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH). 2018.
  5. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
  6. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728.
  7. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389.
  8. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology and Metabolism. 2011;96(1):150-158.
  9. Falutz J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19:1279-87.
  10. Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology. 2007;100:49-58.
  11. Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of Clinical and Translational Science. 2023;7(1):e40.
  12. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240-247.
  13. Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opinion on Investigational Drugs. 2009;18:303-10.
  14. Veldhuis JD, Erickson D, et al. Endogenous Estrogen Regulates Somatostatin-Induced Rebound GH Secretion in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism. 2016;101:4298-4304.
  15. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice. 2026.